Blockchain Registration Transaction Record

Diabetes Drug Cuts AFib Recurrence in Overweight Patients After Ablation

Metformin reduces atrial fibrillation recurrence by 20% in overweight patients after ablation, according to new University of Michigan research presented at AHA Scientific Sessions 2025.

This research matters because it opens up new treatment possibilities for millions of people struggling with recurrent atrial fibrillation, particularly those with obesity who face higher risks of treatment failure. AFib affects over 6 million Americans and significantly increases stroke risk, making effective long-term management crucial. The finding that an inexpensive, widely available generic medication like metformin could substantially improve ablation outcomes represents a potential paradigm shift in cardiovascular care. For patients who have undergone the invasive and costly ablation procedure only to experience recurring episodes, this offers hope for better long-term results without relying solely on additional procedures or stronger medications. The research also highlights how repurposing existing drugs for new indications can accelerate treatment advances while potentially reducing healthcare costs.